Tyra Biosciences' drug TYRA-300 receives Rare Pediatric Disease Designation for achondroplasia from the FDA.

Tyra Biosciences announced it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for TYRA-300 as a potential treatment for achondroplasia, the most common form of dwarfism. The company plans to submit an Investigational New Drug application to the FDA in the second half of 2024 for a Phase 2 clinical trial evaluating multiple dose cohorts of TYRA-300 for children with achondroplasia. The RPD designation aims to expedite the development and review of potential treatments for rare pediatric diseases.

February 01, 2024
9 Articles